Returns | 1W : -16% , 1M : -18.9%,1Y : 30% |
LT :   |
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Average |
ST :   |
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Downward Pledged Shares : None or < 25% |
Peers & Returns | 1W | 1M | 1Y |
BIOCON LTD | -16% | -18.9% | 30% |
SUN PHARMACEUTICAL INDUSTRIES LTD | -4.2% | -3% | 31% |
DR REDDYS LABORATORIES LTD | -3.3% | -5.7% | 67.8% |
DIVIS LABORATORIES LTD | -3.4% | -7.5% | 86.8% |
CIPLA LTD | 1.1% | 1.5% | 82.7% |
AUROBINDO PHARMA LTD | 3.2% | 5.7% | 99.2% |
LUPIN LTD | -1.2% | 9.2% | 46.2% |
TORRENT PHARMACEUTICALS LTD | -2.8% | -5.2% | 29.4% |
CADILA HEALTHCARE LTD | -4.9% | -5.2% | 71.7% |
Ratio | Value |
---|---|
P/E P/B P/S |
60.51
P/E Calculated based on EPS of 6.24
[ Mar2020 - Consolidated Results ] 6.87
P/B Calculated based on Book Value of 54.97
[ Mar2020 - Consolidated Results ] 6.72
P/S Calculated based on Revenues of 6745.2 Cr
[ TTM - Consolidated Results ] |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
208% 131% 99% |
Pledged Shares |
0 % |
---|---|
As on : Sep2020 | |
If less than 25% | Good |
If between 25% and 50% | Neutral |
If greater than 50% | Bad |